Michael J Kelso Selected Research

Michael J Kelso Research Topics

Disease

9	Neoplasms (Cancer) 01/2023 - 01/2008
7	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2008
3	Infections 12/2020 - 05/2013
3	Bacterial Infections (Bacterial Infection) 01/2018 - 01/2017
2	Hypoxia (Hypoxemia) 09/2023 - 01/2019
2	Persistent Infection 12/2020 - 01/2017
2	Clostridium Infections 01/2014 - 01/2014
1	Hypertrophy 09/2023
1	Carcinogenesis 09/2023
1	Fibrosis (Cirrhosis) 09/2023
1	Pulmonary Hypertension 09/2023
1	Vascular Remodeling 09/2023
1	Neuralgia (Stump Neuralgia) 01/2023
1	Acidosis 01/2023
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2022
1	Multiple Myeloma 01/2022
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Inflammation (Inflammations) 01/2019
1	Rheumatoid Arthritis 01/2019
1	Pneumococcal Infections 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2016
1	Hemolysis 11/2015
1	Communicable Diseases (Infectious Diseases) 01/2015
1	Macular Degeneration (Age-Related Maculopathy) 05/2012
1	Breast Neoplasms (Breast Cancer) 01/2008

Drug/Important Bio-Agent (IBA)

9	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2022 - 04/2011
8	Amiloride (Midamor)FDA LinkGeneric 02/2022 - 11/2011
7	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 05/2013
5	Plasminogen Activators (Plasminogen Activator)IBA 09/2023 - 01/2018
5	DiureticsIBA 03/2021 - 11/2011
4	ProdrugsIBA 01/2020 - 01/2017
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2020 - 01/2015
3	PlasminogenIBA 01/2019 - 01/2008
2	trypsin-like serine proteaseIBA 03/2021 - 12/2019
2	5-(N,N-hexamethylene)amilorideIBA 01/2021 - 01/2018
2	Cephalosporins (Cephalosporin Antibiotics)IBA 12/2020 - 01/2020
2	Urokinase Plasminogen Activator ReceptorsIBA 01/2019 - 04/2011
2	PotassiumIBA 01/2018 - 11/2011
1	Semaxinib (SU5416)IBA 09/2023
1	Plasminogen Activator Inhibitor 1IBA 09/2023
1	Mechanistic Target of Rapamycin Complex 1IBA 09/2023
1	Acid Sensing Ion ChannelsIBA 01/2023
1	Coloring Agents (Dyes)IBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	Sodium-Hydrogen ExchangersIBA 03/2021
1	Ceftazidime (Fortum)FDA LinkGeneric 12/2020
1	OxidesIBA 12/2020
1	diazeneIBA 12/2020
1	Nitric Oxide DonorsIBA 01/2020
1	AmidesIBA 01/2019
1	Cytotoxins (Cytolysins)IBA 01/2019
1	EstersIBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	Photosensitizing Agents (Photosensitizers)IBA 01/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018
1	PYRRO-C3DIBA 01/2017
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2017
1	Amoxicillin (Wymox)FDA LinkGeneric 01/2017
1	Angiogenesis InhibitorsIBA 04/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2016
1	Sunitinib (Sutent)FDA Link 04/2016
1	Metronidazole (Metric)FDA LinkGeneric 01/2014
1	Vancomycin FDA LinkGeneric 01/2014
1	FidaxomicinIBA 01/2014
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2012
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2011
1	Sodium-Hydrogen Exchanger 1IBA 11/2011
1	Serine Proteases (Serine Protease)IBA 11/2011
1	Peptides (Polypeptides)IBA 01/2008

Therapy/Procedure

1	Therapeutics 01/2014
1	Photochemotherapy (Photodynamic Therapy) 05/2012